Estados Unidos · Plataformas y datos · Morningstar

Akamis Bio to Present Data from a Phase 1 Study of NG-348 in Patients with Advanced Epithelial Tumors at SITC 2026

Publicado por Morningstar · Estados Unidos hace 19 h

Akamis Bio to Present Data from a Phase 1 Study of NG-348 in Patients with Advanced Epithelial Tumors at SITC 2026 Akamis Bio, a clinical-stage oncology company working to advance…

Leer el artículo completo en Morningstar Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.morningstar.com)

Akamis Bio to Present Data from a Phase 1 Study of NG-348 in Patients with Advanced Epithelial Tumors at SITC 2026

También te puede interesar

Renew outlines FY2027 adjusted EBITDA guidance of INR 105B to INR 109B as take-private process targets Q1 2027 close

Energy Vault (NRGV) Set to Post Quarterly Earnings on Tuesday

Want to help your adult kids and grandkids? Give them money while you’re still alive.

Where Will QuantumScape Stock Be in 5 Years?

Regal Rexnord Q3 2026 slides: organic growth accelerates to 6.1%

Stock market after midterm elections: What S&P 500 history shows

Akamis Bio to Present Data from a Phase 1 Study of NG-348 in Patients with Advanced Epithelial Tumors at SITC 2026

Compartir

También te puede interesar

Renew outlines FY2027 adjusted EBITDA guidance of INR 105B to INR 109B as take-private process targets Q1 2027 close

Energy Vault (NRGV) Set to Post Quarterly Earnings on Tuesday

Want to help your adult kids and grandkids? Give them money while you’re still alive.

Where Will QuantumScape Stock Be in 5 Years?

Regal Rexnord Q3 2026 slides: organic growth accelerates to 6.1%

Stock market after midterm elections: What S&P 500 history shows